The absence of cellular models for Parkinson’s Disease (PD) represents a major bottleneck and unmet need in PD research. Patient-derived induced pluripotent stem cells (iPSCs) offer exciting potential in cell therapy and in vitro disease modeling. Efficient reprogramming of patient somatic cells to iPSCs in feeder-free conditions plays a key role in realizing this potential. Many reprogramming methods have been optimized for use with numerous cell lines, but lead to technical challenges for researchers in converting adult or disease somatic cells to iPSCs consistently and efficiently. The CytoTune®-iPS 2.0 Sendai Reprogramming Kit uses Sendai virus and polycistronic vectors to reprogram somatic cells into induced pluripotent stem cells (iPSCs) which provides a more robust reprogramming efficiency, lower cytotoxicity, and faster viral clearance to generate integration-free iPSCs in feeder-free conditions. In this study, fibroblasts from skin biopsies of two related Parkinson’s disease (PD) study patients were reprogrammed in feeder-free conditions to iPSCs using Life Technologies CytoTune®-iPS 2.0 Sendai Reprogramming Kit. These iPSCs are transgene-free and karyotypically normal, express known pluripotency markers and are able to differentiate into embryoid bodies that present the three germ layer lineages: ectoderm, mesoderm, and endoderm. Gene expression analysis distinguishes these iPSCs from their parental fibroblasts and clusters them together with control Gibco® iPSCs and H9 ESCs. Given the efficiency, speed and ease of reprogramming of these adult, disease-related fibroblasts in feeder-free conditions, the CytoTune®-iPS 2.0 Sendai Reprogramming Kit can be applied to large scale reprogramming of multiple disease lines in an automated fashion to provide significant impact for researchers worldwide